Table 4.
Characteristics of DWI category 3 lesions in peripheral zone
| Characteristics | Overall PSA level | PSA ≤ 10 ng/ml | PSA > 10 ng/ml | ||||||
|---|---|---|---|---|---|---|---|---|---|
| csPCa (n = 53) | non-csPCa (n = 32) | P value | csPCa (n = 19) | non-csPCa (n = 20) | P value | csPCa (n = 34) | non-csPCa (n = 12) | P value | |
| DCE, n (%) | 0.657a | 0.062b | 0.083a | ||||||
| - | 20 (64.5%) | 11 (35.5%) | 7 (77.8%) | 2 (22.2%) | 13 (59.1%) | 9 (40.9%) | |||
| + | 33 (61.1%) | 21 (38.9%) | 12 (40.0%) | 18 (60.0%) | 21 (87.5%) | 3 (12.5%) | |||
| T2WI-score, n (%) | 0.424a | 0.501b | 0.964c | ||||||
| < 4 | 36 (65.5%) | 19 (34.5%) | 14 (53.8%) | 12 (46.2%) | 22 (75.9%) | 7 (24.1%) | |||
| ≥ 4 | 17 (56.7%) | 13 (43.3%) | 5 (38.5%) | 8 (61.5%) | 12 (70.6%) | 5 (29.4%) | |||
| LV, n (%) | < 0.001a | 0.031b | 0.028c | ||||||
| < 0.5 | 22 (45.8%) | 26 (54.2%) | 11 (37.9%) | 18 (62.1%) | 11 (57.9%) | 8 (42.1%) | |||
| ≥ 0.5 | 31 (83.8%) | 6 (16.2%) | 8 (80.0%) | 2 (20.0%) | 23 (85.2%) | 4 (14.8%) | |||
PSA prostate-specific antigen, csPCa clinically significant prostate cancer, T2WI T2-Weighted Imaging, DCE dynamic contrast-enhanced, LV lesion volume
a Chi-square test, b Fisher exact test, c Yates’ correction test